Skip to main content
. 2011 Sep 27;343:d5775. doi: 10.1136/bmj.d5775

graphic file with name jitm871020.f5_default.jpg

Fig 5 Benefits of the quadrivalent and bivalent vaccine that contribute towards the difference in price for the two vaccines to be equally cost effective (median of 10 000 samples). One QALY is assumed to be valued at £30 000. The two benefits of the bivalent vaccine (additional cross protection and in some scenarios longer duration) contribute negatively towards the price difference (that is, they make an equally cost effective quadrivalent vaccine cost less) (see appendix 2 on bmj.com for numerical results and uncertainty intervals)